

Table S1. Construction of paxillin phosphorylation mutants

Primer 1	GA <u>AGA TCT</u> ATG GAC GAC CTC GAC GCC C	<i>Bgl</i> III
Primer 2 (glutamic acid)	GTT TCC AGT TGG GTA TGA <u>CTC</u> GGG GGT CTC C	E
Primer 2' (phenylalanine)	GTT TCC AGT TGG GTA TGA <u>GAA</u> GGG GGT CTC C	F
Primer 3	TCA TAC CCA ACT GGA AAC	
Primer 4	C <u>GAA TTC</u> CTA GCA GAA GAG CTT GAG GAA G	<i>Eco</i> RI
Primer 5 (glutamic acid)	G CTT GTT GGG GAA GCT <u>CTC</u> GAC GTG CTC CTC	E
Primer 5' (phenylalanine)	G CTT GTT GGG GAA GCT <u>GAA</u> GAC GTG CTC CTC	F
Primer 6	AGC TTC CCC AAC AAG C	

Both mutants of paxillin were constructed by PCR, using an identical procedure, and then cloned into YFP-C1 vector (Clontech) using *Bgl*III and *Eco*RI restriction sites. The difference between the two mutants was in primers 2 and 5, in which tyrosine residues 31 and 118 were replaced with glutamic acid for the phosphomimetic mutant (2,5) or with phenylalanine for the non-phosphorylatable mutant (2',5')